A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma

The use of checkpoint inhibitors in advanced and metastatic renal cell carcinomas (RCCs) has rapidly evolved over the past several years. While immune-oncology (IO) drug therapy has been successful at resulting in improved responses and survival, combination therapies with immune checkpoint inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Eun-mi, Linville, Laura, Rosenthal, Matthew, Aragon-Ching, Jeanny B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402652/
https://www.ncbi.nlm.nih.gov/pubmed/34452045
http://dx.doi.org/10.3390/vaccines9080919
_version_ 1783745842501386240
author Yu, Eun-mi
Linville, Laura
Rosenthal, Matthew
Aragon-Ching, Jeanny B.
author_facet Yu, Eun-mi
Linville, Laura
Rosenthal, Matthew
Aragon-Ching, Jeanny B.
author_sort Yu, Eun-mi
collection PubMed
description The use of checkpoint inhibitors in advanced and metastatic renal cell carcinomas (RCCs) has rapidly evolved over the past several years. While immune-oncology (IO) drug therapy has been successful at resulting in improved responses and survival, combination therapies with immune checkpoint inhibitors and vascular endothelial growth factor (VEGF) inhibitors have further improved outcomes. This article reviews the landmark trials that have led to the approval of IO therapies, including the Checkmate 214 trial and combination IO/VEGF TKI therapies with Checkmate 9ER, CLEAR, and Keynote-426, and it includes a discussion on promising therapies moving in the future.
format Online
Article
Text
id pubmed-8402652
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84026522021-08-29 A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma Yu, Eun-mi Linville, Laura Rosenthal, Matthew Aragon-Ching, Jeanny B. Vaccines (Basel) Review The use of checkpoint inhibitors in advanced and metastatic renal cell carcinomas (RCCs) has rapidly evolved over the past several years. While immune-oncology (IO) drug therapy has been successful at resulting in improved responses and survival, combination therapies with immune checkpoint inhibitors and vascular endothelial growth factor (VEGF) inhibitors have further improved outcomes. This article reviews the landmark trials that have led to the approval of IO therapies, including the Checkmate 214 trial and combination IO/VEGF TKI therapies with Checkmate 9ER, CLEAR, and Keynote-426, and it includes a discussion on promising therapies moving in the future. MDPI 2021-08-18 /pmc/articles/PMC8402652/ /pubmed/34452045 http://dx.doi.org/10.3390/vaccines9080919 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Yu, Eun-mi
Linville, Laura
Rosenthal, Matthew
Aragon-Ching, Jeanny B.
A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
title A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
title_full A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
title_fullStr A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
title_full_unstemmed A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
title_short A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
title_sort contemporary review of immune checkpoint inhibitors in advanced clear cell renal cell carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402652/
https://www.ncbi.nlm.nih.gov/pubmed/34452045
http://dx.doi.org/10.3390/vaccines9080919
work_keys_str_mv AT yueunmi acontemporaryreviewofimmunecheckpointinhibitorsinadvancedclearcellrenalcellcarcinoma
AT linvillelaura acontemporaryreviewofimmunecheckpointinhibitorsinadvancedclearcellrenalcellcarcinoma
AT rosenthalmatthew acontemporaryreviewofimmunecheckpointinhibitorsinadvancedclearcellrenalcellcarcinoma
AT aragonchingjeannyb acontemporaryreviewofimmunecheckpointinhibitorsinadvancedclearcellrenalcellcarcinoma
AT yueunmi contemporaryreviewofimmunecheckpointinhibitorsinadvancedclearcellrenalcellcarcinoma
AT linvillelaura contemporaryreviewofimmunecheckpointinhibitorsinadvancedclearcellrenalcellcarcinoma
AT rosenthalmatthew contemporaryreviewofimmunecheckpointinhibitorsinadvancedclearcellrenalcellcarcinoma
AT aragonchingjeannyb contemporaryreviewofimmunecheckpointinhibitorsinadvancedclearcellrenalcellcarcinoma

Ejemplares similares